Literature DB >> 8020837

Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma.

B J Monk1, D S Cha, J L Walker, R A Burger, N S Ramsinghani, A Manetta, P J DiSaia, M L Berman.   

Abstract

The role of adjuvant pelvic radiation following radical hysterectomy and pelvic lymph node dissection in the treatment of stage IB and IIA cervical cancer is controversial. Patients most likely to benefit from postoperative radiation include those with lesions that invade deeply into the cervical stroma, extend into the parametria, or have metastasized to regional lymph nodes. Between 1977 and 1987, 95 patients were treated with this combined regimen at the University of California Irvine Medical Center and Long Beach Memorial Medical Center, including 30 patients with deep cervical stromal invasion alone, 9 patients with parametrial extension alone, 37 patients with lymph node metastasis alone, and 19 patients with both positive nodes and parametrial extension. The estimated 5-year survival for this high-risk population was 67%. Pelvic recurrences alone occurred in 12 (13%) patients, and 14 additional patients (15%) recurred outside of the radiation field. In the node-positive group, the 5-year survival was 78% when the parametrium was not involved but decreased to 39% when parametrial extension was documented (P < 0.05). Patients with grossly involved nodes or multiple nodal metastases were also more likely to recur. Finally, the estimated 5-year survival for patients with deep cervical stromal invasion as the sole indication for radiotherapy was 73%. A retrospective analysis identified tumor grade and cell type also to be of prognostic importance. Severe complications attributable to radiation combined with radical surgery included two small bowel obstructions and one urinary tract fistula. These data suggest that radical hysterectomy, pelvic lymphadenectomy, and adjuvant radiotherapy produce favorable survival results with limited morbidity in patients with high-risk cervical cancer independent of node status except in that subset of patients with both occult parametrial spread and nodal metastasis.

Entities:  

Mesh:

Year:  1994        PMID: 8020837     DOI: 10.1006/gyno.1994.1157

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  15 in total

Review 1.  Adjuvant platinum-based chemotherapy for early stage cervical cancer.

Authors:  Daniela D Rosa; Lídia R F Medeiros; Maria I Edelweiss; Paula R Pohlmann; Airton T Stein
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

2.  The Value of Whole-Tumor Texture Analysis of ADC in Predicting the Early Recurrence of Locally Advanced Cervical Squamous Cell Cancer Treated With Concurrent Chemoradiotherapy.

Authors:  Xiaomiao Zhang; Qi Zhang; Lizhi Xie; Jusheng An; Sicong Wang; Xiaoduo Yu; Xinming Zhao
Journal:  Front Oncol       Date:  2022-05-20       Impact factor: 5.738

3.  Patients treated with neoadjuvant chemotherapy + radical surgery + adjuvant chemotherapy in locally advanced cervical cancer: long-term outcomes, survival and prognostic factors in a single-center 10-year follow-up.

Authors:  Daniela Luvero; Francesco Plotti; Alessia Aloisi; Stella Capriglione; Roberto Ricciardi; Andrea Miranda; Salvatore Lopez; Giuseppe Scaletta; Giovanna De Luca; Pierluigi Benedetti-Panici; Roberto Angioli
Journal:  Med Oncol       Date:  2016-08-30       Impact factor: 3.064

Review 4.  Adjuvant platinum-based chemotherapy for early stage cervical cancer.

Authors:  Frederico S Falcetta; Lídia Rf Medeiros; Maria I Edelweiss; Paula R Pohlmann; Airton T Stein; Daniela D Rosa
Journal:  Cochrane Database Syst Rev       Date:  2016-11-22

5.  The prognosis of women with stage IB1-IIB node-positive cervical carcinoma after radical surgery.

Authors:  Xi Cheng; Shumo Cai; Ziting Li; Meiqin Tang; Muquan Xue; Rongyu Zang
Journal:  World J Surg Oncol       Date:  2004-12-18       Impact factor: 2.754

6.  Could the extent of lymphadenectomy be modified by neoadjuvant chemotherapy in cervical cancer? A large-scale retrospective study.

Authors:  Ting Hu; Xiong Li; Qinghua Zhang; Kecheng Huang; Yao Jia; Ru Yang; Fangxu Tang; Qiang Tian; Ding Ma; Shuang Li
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

7.  Evaluation of outcome and prognostic factors in 739 patients with uterine cervix carcinoma: a single institution experience.

Authors:  Fatma Teke; Adnan Yöney; Memik Teke; Gültekin Adanaş; Zuhat Urakçı; Gül Türkcü; Bekir Eren; Ali İnal; Mustafa Ünsal
Journal:  Contemp Oncol (Pozn)       Date:  2015-05-13

8.  N6-Methyladenosine Associated Silencing of miR-193b Promotes Cervical Cancer Aggressiveness by Targeting CCND1.

Authors:  Chunxian Huang; Jinxiao Liang; Shaodan Lin; Dongyan Wang; Qingsheng Xie; Zhongqiu Lin; Tingting Yao
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

9.  Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan.

Authors:  Yuji Ikeda; Akiko Furusawa; Ryo Kitagawa; Aya Tokinaga; Fuminori Ito; Masayo Ukita; Hidetaka Nomura; Wataru Yamagami; Hiroshi Tanabe; Mikio Mikami; Nobuhiro Takeshima; Nobuo Yaegashi
Journal:  J Gynecol Oncol       Date:  2016-05       Impact factor: 4.401

10.  Lymphadenectomy and adjuvant therapy in endometrial carcinoma: role of adjuvant chemotherapy.

Authors:  I Otsuka; T Kubota; T Aso
Journal:  Br J Cancer       Date:  2002-08-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.